UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 12 von 1280
Datensatz exportieren als...
BibTeX
Glucose as a prognostic factor in ovarian carcinoma
Cancer, 2009-03, Vol.115 (5), p.1021-1027
Lamkin, Donald M.
Spitz, Douglas R.
Shahzad, Mian M. K.
Zimmerman, Bridget
Lenihan, Daniel J.
DeGeest, Koen
Lubaroff, David M.
Shinn, Eileen H.
Sood, Anil K.
Lutgendorf, Susan K.
2009
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Lamkin, Donald M.
Spitz, Douglas R.
Shahzad, Mian M. K.
Zimmerman, Bridget
Lenihan, Daniel J.
DeGeest, Koen
Lubaroff, David M.
Shinn, Eileen H.
Sood, Anil K.
Lutgendorf, Susan K.
Titel
Glucose as a prognostic factor in ovarian carcinoma
Ist Teil von
Cancer, 2009-03, Vol.115 (5), p.1021-1027
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2009
Quelle
MEDLINE
Beschreibungen/Notizen
BACKGROUND: Research suggests that glucose levels in cancer patients may be an important prognostic indicator. In ovarian tumors, increased expression of glucose transporter 1 (GLUT1), a transmembrane protein responsible for glucose uptake, is related to shorter survival time in ovarian cancer patients. This study tested the hypothesis that higher presurgical glucose levels predict shorter disease‐specific survival time and time to recurrence in ovarian cancer patients. METHODS: Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Survival time and time to recurrence (disease‐free interval [DFI]) were ascertained from medical records. Cox proportional hazards regression models were used to estimate the hazard ratio (HR) for survival time and DFI in relation to glucose level, adjusting for body mass index (BMI), stage, grade, and cytoreduction as appropriate. RESULTS: Higher glucose levels were associated with shorter survival times in univariate analyses (HR, 1.88; P = .05). Multivariate analysis adjusting for stage showed that higher glucose levels were associated with shorter survival times (HR, 2.01; P = .04) and DFI (HR, 2.32; P = .05). In the validation set, higher glucose levels were associated with shorter survival times (HR, 2.01; P = .02) and DFI (HR, 2.48; P = .001) in univariate analysis, although glucose was not independent of the effect of cytoreduction when predicting survival time in this latter set. CONCLUSIONS: These findings contribute to mounting evidence that glucose levels have prognostic value in ovarian carcinoma. Cancer 2009. © 2009 American Cancer Society. Nonfasting plasma glucose levels were determined for 74 patients with ovarian cancer at the time of their presurgical consultation and for 125 ovarian cancer patients in an independent validation set. Higher glucose levels were associated with significantly shorter survival time and shorter time to recurrence.
Sprache
Englisch
Identifikatoren
ISSN: 0008-543X
eISSN: 1097-0142
DOI: 10.1002/cncr.24126
Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2649990
Format
–
Schlagworte
Adult
,
Aged
,
Biological and medical sciences
,
Blood Glucose - analysis
,
cancer
,
Disease-Free Survival
,
Female
,
Female genital diseases
,
glucose
,
Gynecology. Andrology. Obstetrics
,
Humans
,
Medical sciences
,
Middle Aged
,
ovarian cancer
,
Ovarian Neoplasms - blood
,
Ovarian Neoplasms - mortality
,
Preoperative Care
,
Prognosis
,
recurrence
,
Survival Analysis
,
survival rate
,
Tumors
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX